Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]
In development
Reference number: GID-TA11477
Expected publication date: TBC
This topic will now be progressed as a Multiple Technology Appraisal (MTA) alongside the following topic;
Resmetirom for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis [ID6529]
The Invitation to Participate (ITP) will now be issued week commencing 07 July 2025 and the MTA title and ID number is:
Resmetirom and semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis [ID6458]